Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10612
Title: Targeted therapies in the treatment of renal cell carcinoma.
Authors: Pezaro, Carmel;Davis, Ian D
Affiliation: Ludwig Institute Oncology Unit, Austin Health, Melbourne, Victoria, Australia.
Issue Date: 2008
Citation: Current Medicinal Chemistry; 15(12): 1166-74
Abstract: The management of renal cell carcinoma (RCC) has undergone rapid and radical evolution over the last few years. An improved understanding of the underlying biology of RCC has led to the approval of several new therapies directed against specific and relevant biological targets, so-called "targeted therapies." These highly effective treatments are now entering routine use, however many questions still remain as to how best to use these agents and integrate them into the broader therapeutic armamentarium. This review summarizes the major published clinical trials of the new agents, discusses the controversies and research questions that have arisen as a result, and considers some of the issues that remain.
Internal ID Number: 18473811
URI: http://ahro.austin.org.au/austinjspui/handle/1/10612
URL: http://www.ncbi.nlm.nih.gov/pubmed/18473811
Type: Journal Article
Subjects: Angiogenesis Inhibitors.therapeutic use
Animals
Antineoplastic Agents.therapeutic use
Carcinoma, Renal Cell.blood supply.drug therapy
Clinical Trials as Topic
Humans
Kidney Neoplasms.blood supply.drug therapy
Receptor, Epidermal Growth Factor.drug effects
Regional Blood Flow.drug effects
Signal Transduction.drug effects
Vascular Endothelial Growth Factor A.drug effects
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.